EICHORCondition: Fibrodysplasia Ossificans Progressiva · Sponsor: Regeneron Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California Los Angeles (UCLA) Medical Center | Los Angeles, California, United States | — |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | — |
| Royal North Shore Hospital | St Leonards, New South Wales, Australia | — |
| Hospital Israelita Albert Einstein | São Paulo, Brazil | — |
| Universidad de Concepcion | Concepción, Biobio, Chile | — |
| Tongji Hospital of Tongji University | Shanghai, China | — |
| Clinica Universidad de La Sabana | Chía, Cundinamarca, Colombia | — |
| HUS Children and Adolescents Park Hospital Clinical Trial Unit | Helsinki, Stenbäckinkatu 11, Finland | — |
| Hôpital Lapeyronie | Montpellier, France | — |
| Hopital Lariboisiere | Paris, France | — |
| Queen Mary Hospital | Hong Kong, Hong Kong | — |
| IRCCS Istituto Giannina Gaslini | Genoa, Italy | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05394116